ELISA News and Research

RSS

8.5 percent of COVID-19 patients do not seroconvert

A new study published on the preprint server medRxiv in June 2020 reports on the use of inexpensive and accurate ELISA and rapid diagnostic tests (RDT) to identify the demographic and clinical factors that affect the antibody response in COVID-19 patients.

23 Jun 2020

Characterizing SARS-CoV-2 convalescent plasma

A new study published on the preprint server bioRxiv in June 2020 uses serologic correlates to assess the efficacy of convalescent plasma. This will also help to classify donor plasma as more or less potent at neutralizing the virus.

23 Jun 2020

Novel vaccine platform against COVID-19 based on engineered human mesenchymal stem cells

In a recent groundbreaking bioRxiv paper, Chinese researchers describe a novel approach towards coronavirus disease (COVID-19) vaccine design based on engineered human mesenchymal stem cells, with favorable and promising antibody response.

22 Jun 2020

Reassuring news on the Oxford vaccine (AZD1222) against SARS-CoV-2

A new paper from the UK vaccine research group, currently available on the bioRxiv preprint server, reveals that a single dose of ChAdOx1 nCoV-19 (AZD1222) can induce antigen-specific antibody and T cells responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a booster shot additionally enhances antibody production with an increase in neutralizing titers – particularly in pigs.

22 Jun 2020

A highly sensitive and specific antibody test for COVID-19

A new proof-of-concept study by UK researchers, currently available on the medRxiv* preprint server, describes the development of an enzyme-linked immunosorbent assay that can be used when lower levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific-antibodies are present in serum and saliva samples.

21 Jun 2020

Integrin-binding peptide ATN-161: Potential COVID-19 treatment

Now, a new study by researchers at Tulane University and published on the preprint server bioRxiv* in June 2020 reports the potential role of an integrin inhibitor ATN-161 to prevent ACE2-S protein binding.

17 Jun 2020

Testing reveals 11 percent of people in Geneva infected with SARS-CoV-2

Now, a team of researchers at Geneva University Hospitals has found that less than 11 percent of the population in Geneva has contracted the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Their research is published in the journal The Lancet.

15 Jun 2020

Synthetic nanobodies potent neutralizers for SARS-CoV-2

Researchers at the Chinese Academy of Sciences report the generation of potent synthetic nanobodies that selectively and efficiently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus.

11 Jun 2020

Treatment with vitamin A analog improves visual function in diabetic mice

Diabetic retinopathy is a common complication of diabetes and a leading cause of blindness among the working-age population.

11 Jun 2020

Rapid point-of-care testing using screen-printed electrodes from Metrohm DropSens

Point-of-care testing with screen-printed electrodes allows rapid testing of populations for viral outbreaks – at affordable costs, without the need for trained specialists and/or complicated equipment.

From Metrohm USA Inc. 11 Jun 2020

Scientists investigate immune responses to SARS-CoV-2 spike immunogens

The coronavirus pandemic is actively spreading across the globe, with millions of people infected. Amid the global health crisis, scientists race to develop an effective vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

10 Jun 2020

Synthetic monoclonal antibodies effectively neutralize SARS-CoV-2 in laboratory conditions

In a new study available on the preprint server bioRxiv*, a multinational research group demonstrated how monoclonal antibodies strongly inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro at even sub-nanomolar concentrations. This makes them a prime candidate for the treatment of coronavirus disease (COVID-19).

8 Jun 2020

Improving detection of SARS-CoV-2 infection among severely ill children

Researchers in the UK have conducted a study showing that children with a severe inflammatory syndrome had high levels of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), despite having tested negative for the virus by polymerase chain reaction (PCR).

8 Jun 2020

Monocytes could be critical in dysregulated immunity in COVID-19

A new study by Spanish researchers as part of the GEN-COVID Project, and published on the preprint server medRxiv* in June 2020, suggests that monocytes are primarily involved in triggering the hyperinflammatory immune response that may underlie severe COVID-19 infection.

8 Jun 2020

A SARS-CoV-2 antibody magnetic immuno-detection test

A new report, released on the preprint server bioRxiv by researchers at the Fraunhofer Institute for Molecular Biology and Applied Ecology, describes the development of an innovative serologic test that could provide a fast, easy, and inexpensive method of detecting high titers of antibody in the serum of SARS-CoV-2 infected people.

4 Jun 2020

Preventing novel coronavirus from entering into a host cell

How might the novel coronavirus be prevented from entering a host cell in an effort to thwart infection? A team of biomedical scientists has made a discovery that points to a solution.

30 May 2020

Changes in gut mucus are linked to brain disorders

Mucus is the first line of defense against bad bacteria in our gut. But could it also be part of our defense against diseases of the brain?

29 May 2020

Ferritin heavy chain protein shows promise as a potential SARS-CoV-2 vaccine or antiviral

A new study published on the online preprint server bioRxiv in May 2020 reports the construction and testing of a new ferritin-based antigen-bearing protein that has biological activity towards the ACE2 receptor. This could indicate its potential for development as a vaccine or antiviral.

28 May 2020

SignalChem Biotech Inc. launches COVID-19 elisa kits for diagnostic research

SignalChem, a global leader in cell signaling and protein engineering, has been conducting research on new coronaviruses since the outbreak of the virus.

From SignalChem Biotech Inc. 28 May 2020

CanSino's potential coronavirus vaccine triggers immune response in clinical trial

Scientists across the globe are racing to develop a vaccine that can provide protection against coronavirus disease (COVID-19). An effective and safe vaccine would curb not only the current coronavirus pandemic but also prevent future outbreaks

27 May 2020